Business Context and Reporting Period
Company: BioSig Technologies, Inc. (Note: Input metadata referenced "Streamex Corp.", but the filing text identifies the registrant as BioSig Technologies, Inc., trading as BSGM on the NASDAQ Capital Market).
Reporting Period: Quarterly period ended March 31, 2025 (Form 10-Q).
Business Overview: BioSig is a medical device technology company developing the PURE EP™ Platform for electrophysiology ablation treatments. The company has pivoted from hardware commercialization to software algorithm R&D. It operates as a single segment and holds majority interests in subsidiaries ViralClear Pharmaceuticals, Inc. (69.08%) and BioSig AI Sciences, Inc. (84.5%).
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $0 | $14,000 |
| Net Loss (Attributable to Common Shareholders) | $(2,814,000) | $(3,537,000) |
| Net Loss Per Share (Basic & Diluted) | $(0.14) | $(0.36) |
| Cash and Cash Equivalents (End of Period) | $3,727,000 | $416,000 |
| Working Capital | $2,307,000 | $(1,920,000) |
| Operating Cash Flow | $(1,115,000) | $(1,314,000) |
| Financing Cash Flow | $4,700,000 | $1,540,000 |
| Total Assets | $4,418,000 | $842,000 |
| Total Liabilities | $1,679,000 | $2,264,000 |
Material Changes vs. Prior Period
- Liquidity Improvement: Cash balances increased significantly from $142,000 to $3.73 million, driven by $4.7 million in financing activities, including $3.88 million from At-The-Market (ATM) offerings and $818,000 from private placements.
- Revenue Decline: Revenue dropped to zero from $14,000 in the prior year quarter, reflecting a strategic shift away from hardware sales toward R&D.
- Expense Reduction: Total operating expenses decreased by $467,000 (13.5%) to $2.98 million. Research and Development (R&D) expenses fell 97.5% to $6,000 due to reduced payroll and clinical study costs.
- Non-Cash Gains: The company recorded a $199,000 gain on the settlement and extinguishment of accounts payable, partially offsetting the operating loss.
- Stock-Based Compensation: Stock-based compensation expense increased significantly to $2.07 million, primarily due to the issuance of shares for services and debt settlement.
Outlook, Risks, and Unusual Items
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern due to recurring net losses and negative operating cash flows. Continued operations depend on securing additional financing.
- Merger Proposal: On May 5, 2025 (subsequent event), the company entered a Letter of Intent to merge with Streamex Exchange Corporation. Post-merger, Streamex shareholders would own approximately 75% of the combined entity.
- Nasdaq Compliance: The company received a notice regarding minimum bid price non-compliance in April 2025 but regained compliance by May 13, 2025, after maintaining a $1.00 closing bid for 10 consecutive days.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, specifically regarding stock-based compensation recording, period-end review processes, and segregation of duties.
- Legal Settlement: A litigation threat regarding alleged unlawful actions was settled in March 2025 with an accrued liability of $493,800, which was subsequently settled via stock issuance in April 2025.
- Equity Line of Credit: The company entered an agreement with Lind Global Fund III, LP for a potential $5.0 million equity line of credit, subject to SEC registration.
Investor Verification Checklist
- Merger Terms: Verify the definitive agreement terms for the proposed merger with Streamex Exchange Corporation and the resulting dilution to existing shareholders.
- Capital Runway: Assess the sufficiency of the $3.7 million cash balance against the burn rate of ~$1.1 million per quarter to determine the timeline for the next capital raise.
- Revenue Model: Confirm the timeline for monetizing the new software-focused R&D strategy, given the current lack of revenue.
- Internal Control Remediation: Review the progress of the remediation plan for material weaknesses in financial reporting to ensure future filing reliability.
- Preferred Stock Obligations: Monitor the $105,000 liquidation preference and dividend obligations on Series C Preferred Stock, which could be triggered by bankruptcy or judgments over $100,000.